Why Diversity Matters in Rare Disease Biospecimen Research

Photo credit: https://blogs.cdc.gov/genomics/2019/04/04/introducing-the-rare-diseases/

The promise of precision medicine rests fundamentally on understanding how genetic variation, ancestry, environmental exposures, and social determinants of health interact to shape disease risk, manifestation, and therapeutic response. Yet rare disease biospecimen repositories and research cohorts have historically demonstrated significant demographic and genetic homogeneity, predominantly sampling individuals of European ancestry living in metropolitan areas with access to specialized academic medical centers. This lack of diversity creates scientific limitations that extend far beyond issues of research equity, fundamentally constraining our understanding of rare disease biology, limiting the generalizability of research findings, and potentially creating disparities in therapeutic access and effectiveness across populations.

Recent analyses reveal that approximately 95% of rare diseases still lack approved therapies, with equity in rare disease research remaining a persistent challenge as non-Caucasian populations remain underrepresented in clinical trials and genetic studies. As the rare disease therapeutic landscape evolves toward gene therapies, precision diagnostics, and biomarker-directed interventions, the consequences of this representation gap will intensify unless deliberate strategies address diversity in biospecimen collection and research participation.

The Genetic Architecture of Rare Disease Diversity

Rare disease genetic variation demonstrates clear clustering patterns across different populations, geographic locations, and ancestry groups. Founder effects, population bottlenecks, consanguinity rates, and migration patterns have created population-specific distributions of disease-causing variants.

Beyond simple prevalence differences, the specific mutations causing rare diseases often differ across populations, with corresponding implications for phenotypic presentation, disease severity, and therapeutic response. A gene therapy designed and validated using homogeneous cohorts may show reduced efficacy in patients carrying population-specific variants more common in diverse ancestry groups. Similarly, diagnostic assays validated exclusively in homogeneous cohorts may demonstrate reduced sensitivity or specificity when applied to genetically diverse populations.

The growing recognition that rare disease genetic variation tends to cluster within different populations creates both scientific imperatives and ethical obligations to ensure biospecimen repositories reflect human diversity. Researchers investigating genotype-phenotype relationships require access to diverse immune and cellular materials such as PBMCs, CD3+ T cells, and NK cells representing the full mutation spectrum.

Phenotypic Heterogeneity Across Populations

While genetic variation represents an obvious driver of population-level diversity in rare diseases, phenotypic differences across populations also reflect environmental exposures, dietary patterns, healthcare access, and epigenetic factors that modify disease expression.

Biospecimen-based research investigating gene-environment and modifier interactions often relies on multiple specimen types including whole blood, serum, and plasma. These materials enable correlation of circulating biomarkers with clinical phenotypes across populations.

Similarly, rare diseases with inflammatory or immune-mediated components may demonstrate phenotypic differences across populations due to variation in immune pathways. Tissue-level studies using skin punch biopsy samples or inflammatory matrices like synovial fluid help identify population-specific disease mechanisms.

Biomarker Validation Requires Population Diversity

The pathway from biomarker discovery to clinical validation demands demonstration that candidate biomarkers perform reliably across the populations for which they are intended. A diagnostic biomarker validated exclusively in a narrow population may show reduced diagnostic accuracy elsewhere due to baseline biological variation.

Comprehensive validation studies frequently depend on large sample volumes such as bulk plasma collections alongside matched plasma and serum samples across ancestry groups. These enable reference range development and assay performance testing.

For predictive biomarkers guiding therapy selection, diversity becomes even more critical. Biospecimen-based validation studies that lack representation risk developing clinical decision tools that work well for some populations while performing poorly for others.

Addressing Systematic Barriers to Diversity in Biospecimen Collection

The underrepresentation of diverse populations reflects multiple intersecting barriers including geography, socioeconomic constraints, and historical mistrust of research institutions. Direct-to-patient collection programs, multilingual engagement, and partnerships with community health centers are essential to overcoming these barriers.

Mobile collection programs enable access to advanced cellular collections including leukopak and GMP leukopak products outside traditional academic centers, helping ensure diverse immune cell representation.

Genetic Counseling and Return of Results Considerations

As rare disease biospecimen research increasingly incorporates whole-genome sequencing and advanced molecular characterization, questions about return of results and genetic counseling become more complex. Different communities hold varying perspectives on predictive genetic information and incidental findings.

Diverse genomic datasets built from cellular collections such as PBMCs and immune subsets improve variant interpretation accuracy across populations and reduce misclassification in global databases.

Precision Medicine Requires Precision in Population Representation

The vision of precision medicine promises therapies tailored to individual genetic profiles and disease subtypes. Realizing this vision requires representative biospecimen resources spanning genetic and phenotypic diversity.

Therapeutic development increasingly relies on immune characterization workflows combining PBMC isolation, subset purification such as T cells and NK cells, and translational biomarker measurement in plasma or serum.

Creating Inclusive Research Ecosystems

Addressing diversity gaps requires systematic change across research infrastructure, funding priorities, and institutional culture. Biospecimen repositories must actively monitor demographic characteristics of collections and implement recruitment strategies designed to achieve representation goals rather than passively accepting convenience samples.

From Study Design to Receipt of Samples: Building Equitable Biospecimen Infrastructure

Creating representative rare disease biospecimen resources requires intentional design from early study planning stages. Inclusion criteria, recruitment strategies, and participant compensation policies must be evaluated for bias.

Sanguine’s direct-to-patient collection infrastructure supports nationwide recruitment and enables diverse participation while maintaining rigorous quality standards from study design to receipt of samples.